Cargando…
Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
PURPOSE: Paclitaxel-based chemotherapy continues to be an integral component in the treatment of many solid tumors. Prolonged use of paclitaxel may result in repeated doses of premedications and potential unwanted side effects. Infusion hypersensitivity reactions occurring beyond the second dose are...
Autores principales: | Berger, Michael J., Dunlea, Leslie J., Rettig, Amy E., Lustberg, Maryam B., Phillips, Gary S., Shapiro, Charles L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411299/ https://www.ncbi.nlm.nih.gov/pubmed/22089428 http://dx.doi.org/10.1007/s00520-011-1303-9 |
Ejemplares similares
-
No need for H(2)-antagonists in premedication regimens for paclitaxel infusions: less is more
por: Gelderblom, Hans, et al.
Publicado: (2021) -
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
por: Kloover, J S, et al.
Publicado: (2004) -
The efficacy of single premedication with antihistamines for radiocontrast media hypersensitivity
por: Lee, So-Hee, et al.
Publicado: (2016) -
Effectiveness of premedication for hypersensitivity reactions to radiocontrast media in one tertiary hospital
por: Jung, JaeWoo, et al.
Publicado: (2014) -
Oral premedication in patients with a history suggesting hypersensitivity to iodinated contrast media
por: Specjalski, Krzysztof, et al.
Publicado: (2020)